Showing 6621-6630 of 8682 results for "".
- New Intervention Boosts Sunscreen Usehttps://practicaldermatology.com/news/new-intervention-boosts-sunscreen-use/2467338/New research puts forth a potential approach for promoting sunscreen use to combat the persistent prevalence of skin cancer. "While the risks of not wearing sunscreen are well-documented, there are no effective interventions to promote sunscreen use across populations, and existing interv
- Study: Dupilumab Shows Sustained Benefit for Severe ADhttps://practicaldermatology.com/news/study-dupilumab-shows-sustained-benefit-severe-ad/2467337/New research on the long-term safety and efficacy of dupilumab in adults with moderate to severe atopic dermatitis (AD) indicates that dupilumab was safe and effective in the long-term treatment of the condition. The open-label extension study was conducted over a period of 5 years in 28
- Study: Omega-3 Supplementation Reduces Acne Severityhttps://practicaldermatology.com/news/study-omega-3-supplementation-reduces-acne-severity/2467299/New research suggests there may be potential benefits of omega-3 fatty acids (ω-3 FA) in managing acne severity through dietary intervention and supplementation. Study researchers publishing in the Journal of Cosmetic Dermatology focused their efforts on eicosapentaenoic acid (EP
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://practicaldermatology.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS Englandhttps://practicaldermatology.com/news/nice-recommends-ebglyss-lebrikizumab-use-moderate-severe-ad-nhs-england/2467288/Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England. Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older
- Almirall Announces New Sustainability Strategyhttps://practicaldermatology.com/news/almirall-announces-new-sustainability-strategy/2467252/The five pillars of Planet, People, Patients, Partners, and Principles are at the center of Almirall S.A.’s new sustainability strategy, Act4Impact 2030, the company announced. The updated strategy aims at transforming the company’s sustainability roadmap and consists of 20 strategic lines
- NEA Study Illuminates Gaps in Mental Health Help for Eczema Patientshttps://practicaldermatology.com/news/nea-study-illuminates-gaps-mental-health-help-eczema-patients/2467195/Forty-two percent of patients with atopic dermatitis (eczema) and caregivers of children/teens with the condition never spoke about mental health with primary eczema care providers, according to National Eczema Association (NEA
- POSITIVE: Tildrakizumab Shows Effectiveness in Psoriasis Patients at 52 Weekshttps://practicaldermatology.com/news/positive-tildrakizumab-shows-effectiveness-psoriasis-patients-52-weeks/2467194/New one-year data presented at the International Federation of Psoriasis Associations (IFPA) Conference 2024 showed that tildrakizumab (Illumetri, Almirall) was effective at restoring and maintaining wellbeing of patients with moderate-to-severe psoriasis. Researchers for the POSITIVE st
- Stigmatization Based on Skin Disorders Linked with Diminished Life Quality in Pediatric Patientshttps://practicaldermatology.com/news/stigmatization-based-skin-disorders-linked-diminished-life-quality-pediatric-patients/2467151/New research suggests that skin disorder-based stigmatization is perhaps unsurprisingly associated with a diminished quality of life and poorer mental health. Researchers conducted a cross-sectional, single-visit study that included 1,671 children (57.9% female) across 32 pediatric center
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever